Supplementary Figures from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion

Supplementary Figure S1-S9. Figure S1. Specificity of antibody directed against the L2Δ13 splice form of LOXL2 in histological analysis. Figure S2. LOXL2 and L2Δ13 promote ESCC cell migration and invasion. Figure S3. Histological analysis of tumors and popliteal lymph nodes derived from the xenografts. Figure S4. LOXL2 and L2Δ13 interact with actin-binding proteins ezrin, fascin, HSPB1 and TMOD3. Figure S5. Co-localizations of L2Δ13 with four cytoskeletal binding proteins in ESCC cells. Figure S6. Kaplan-Meier curves and log-rank tests of fascin, HSPB1 and TMOD3 for overall survival and disease-free survival in ESCC patients. Figure S7. Molecular models of LOXL2/L2Δ13 and its actin-binding interacting partners predict poor prognosis in ESCC patients. Figure S8. LOXL2 is an oncogenic modulator in the activation of ezrin via phosphorylating ezrin at T567. Figure S9. LOXL2 modulates PKC-stimulated ezrin-T567 phosphorylation in ESCC cells.